John F. Paolini - Mar 16, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol: KNSA
Transactions as of: Mar 16, 2023
Transactions value $: -$17,798
Form type: 4
Date filed: 3/20/2023, 05:20 PM
Previous filing: Nov 9, 2022
Next filing: Apr 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+1.73K	+4.75%		38.1K	Mar 16, 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	-$5.81K	-507	-1.33%	$11.46	37.6K	Mar 16, 2023	Direct
transaction	KNSA	Class A Common Share	Options Exercise		+3.67K	+9.78%		41.2K	Mar 20, 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	-$12K	-1.08K	-2.61%	$11.12	40.1K	Mar 20, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-1.73K	-33.33%	$0.00	3.45K	Mar 16, 2023	Class A Common Share	1.73K		Direct	F1, F2
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-3.67K	-100%	$0.00^*	0	Mar 20, 2023	Class A Common Share	3.67K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.
F3	The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.